title: Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
abstract: Recombinant (r) hirudin is a potent thrombin-specific inhibitor originally derived from the natural hirudin of the leech (Hirudo medicinalis). We have studied the efficacy of r-hirudin compared to heparin in a dog model of cardiopulmonary bypass (CPB) surgery. Two administration regimens were used for r-hirudin: Group I received 1.0 mg/kg intracardiac (i.c.) bolus then intravenous (i.v.) bolus at 30 min (n = 10); Group II received 1.0 mg/kg (i.c.) bolus with 1.25 +/- 0.04 mg/kg/h (i.v.) infusion (n = 8). Group III was given heparin 1.66 mg/kg (i.c.) bolus (n = 9). Aspiration of blood from the chest cavity revealed no significant difference between the three groups. Measurement of fibrin deposits in the pump line filter revealed higher amounts in the r-hirudin groups (P = 0.02). Decreases in platelets, fibrinogen and haematocrit due primarily to haemodilution were the same in each group. The bleeding time was less prolonged for r-hirudin than for heparin (p less than 0.001). No antagonist for r-hirudin was used; however, due to its short half-life, all coagulation parameters returned to baseline within 30 min after CPB. Since r-hirudin has no effect on platelets, is a poor immunogen, does not require a plasma cofactor, and may not require an antagonist, it may provide an alternative anticoagulant to heparin in CPB. Additional studies are, however, needed to optimize the dose and to evaluate other clinical aspects of r-hirudin.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois 60153.
authors.forename: J M
authors.initials: JM
authors.lastname: Walenga
authors.forename: M
authors.initials: M
authors.lastname: Bakhos
authors.forename: H L
authors.initials: HL
authors.lastname: Messmore
authors.forename: M
authors.initials: M
authors.lastname: Koza
authors.forename: M
authors.initials: M
authors.lastname: Wallock
authors.forename: E
authors.initials: E
authors.lastname: Orfei
authors.forename: J
authors.initials: J
authors.lastname: Fareed
authors.forename: R
authors.initials: R
authors.lastname: Pifarre
mesh_terms: D000818:Animals; D001760:Bleeding Time; D016063:Blood Loss, Surgical; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D004285:Dogs; D005112:Extracorporeal Circulation; D005337:Fibrin / Q000032:analysis; D006400:Hematocrit; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006629:Hirudins / Q000008:administration & dosage / Q000494:pharmacology; D007262:Infusions, Intravenous; D007267:Injections; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013918:Thrombin Time; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D006629:Hirudins; D011994:Recombinant Proteins; D005337:Fibrin; D006493:Heparin